Microdosing Tirzepatide Schedule: How Providers Actually Build One

That's worth saying plainly, because the internet is currently full of confident-looking tirzepatide microdosing schedules, and they can't all be right for you for a simple reason: they weren't built for you. The standard schedule is the only official one, with Zepbound starting at 2.5 mg weekly and climbing a fixed ladder toward 15 mg.^[1] A microdosing schedule works differently. It starts lower, moves slower, and changes based on how your body responds, which is exactly why you won't find one printed on a label. Any chart you do find, including our own microdosing tirzepatide chart, is a starting framework a provider adjusts, not a plan to follow on your own.

What Counts as a Microdosing Schedule for Tirzepatide?

A microdosing schedule is any dosing plan that deliberately stays below the standard ladder, and the word doing the work in that sentence is deliberately. The label's reason for climbing is maximum weight loss. A microdosing schedule exists for different reasons entirely: keeping weight off after a loss, controlling appetite with fewer side effects, or simply finding the least medication that does the job. Where the standard schedule asks how high you can comfortably go, a microdosing schedule asks how low you can stay while it still works, and those two questions produce very different plans.

In practice, providers building these plans work with weekly doses somewhere between roughly 0.5 and 2.5 mg. Below 2.5 mg, no manufactured pen or vial exists, so those doses are prescribed as personalized compounded tirzepatide, documented for you specifically by your prescriber.^[6] That's also why a real schedule and a real provider come as a package deal. If it's the dose amounts themselves you're after, our microdosing tirzepatide chart shows the monthly framework Josie providers start from.

How a Provider-Built Schedule Is Structured

Nearly every provider-built schedule follows the same three design rules, even though the actual numbers differ from patient to patient.

Start below the standard starting dose. The label's 2.5 mg first month is already called a starting dose rather than a treatment dose,^[1] and microdosing plans typically begin under it, sometimes well under. That's especially true for women who were sensitive to GLP-1 side effects in the past, and for women who are maintaining a result rather than chasing a new one.

Hold longer at each level. Where the label moves every 4 weeks, microdosing schedules commonly sit at one dose for 4 to 8 weeks or longer, because the question being answered at each level is "is this enough?", and your body needs time to show you.

Move on signals, not on the calendar. The signals that prompt a step up are appetite and food noise returning, a maintenance trend drifting upward for several weeks, or a plateau you and your provider agreed to push past. The signals for holding or stepping down are nausea, fatigue, faster loss than you wanted, or simply the happy discovery that the current dose is doing its job.

How the Schedule Adjusts in Midlife

More slowly, and more often, is the short answer, because midlife changes the math in ways a 30-year-old's schedule never has to account for.

Estrogen decline shifts appetite signaling and where fat gets stored, and it can quietly change how you tolerate the same dose from one season to the next. A dose that held perfectly through spring can feel weaker after months of poor sleep and rising stress, or suddenly too strong, through no failure of yours. Providers who work with midlife women treat the schedule as a moving target, reviewed at set intervals, adjusted in small steps, and coordinated with anything else that's changing, including hormone therapy.

There's one more midlife-specific reason to favor slower schedules, and it's muscle. After 50, lost weight includes muscle, not just fat, unless you actively protect it, and slower loss with enough protein and strength training is far easier on muscle than fast loss. A lower, slower schedule is one of the levers for keeping the body you'll want at 70.

What the Evidence Does and Does Not Show

The honest answer is that the trials prove tirzepatide works at full doses, and nothing published yet tests the microdose schedules built beneath them. SURMOUNT-1 found up to about 21% average body-weight loss at 72 weeks on 10 to 15 mg,^[3] and SURMOUNT-4 showed that people who stopped regained most of their lost weight within a year while those who continued kept losing.^[4] That's strong evidence that ongoing medication maintains results. It just isn't evidence about microdoses specifically, and most sites selling microdosing would prefer you not dwell on the difference.

A Harvard endocrinologist put it bluntly this year: there are no legitimate long-term data on microdosing yet, and not even a standard definition of it.^[2] A registered clinical trial is now underway, which should start filling the gap.^[5] None of this means microdosing is fake. It means a microdosing schedule is a clinical judgment call built on how the drug behaves in the body, the full-dose evidence, and your own response, which is exactly why it should run through a provider who tracks your results. Anyone handing you a fixed schedule with no review built in is selling, not treating.

Getting a Schedule Built for You

A real schedule starts with a real review: your history, your goal, the doses you've used before and how they felt, and where you are hormonally. From there your provider sets a starting dose, a hold length, and the signals you'll both watch, and then the plan gets revisited, because the right dose this year may not be the right dose next year.

If you want to see the framework Josie providers start from, the tirzepatide chart and the broader guide to how GLP-1 microdosing works are the next two reads. And if you'd rather see what this looks like as actual care, Josie's provider-built microdose plans are where a schedule stops being theory.